Prevalence, Reasons for Use, and Risk Perception of Electronic Cigarettes among Post-Acute Coronary Syndrome Smokers by Busch, Andrew M. & Tooley, Erin M.
Roger Williams University
DOCS@RWU
Feinstein College of Arts & Sciences Faculty
Publications Feinstein College of Arts and Sciences
2016
Prevalence, Reasons for Use, and Risk Perception of
Electronic Cigarettes among Post-Acute Coronary
Syndrome Smokers
Andrew M. Busch
Miriam Hospital, Providence, RI
Erin M. Tooley
Roger Williams University, etooley@rwu.edu
Follow this and additional works at: http://docs.rwu.edu/fcas_fp
Part of the Health Psychology Commons, and the Public Health Commons
This Article is brought to you for free and open access by the Feinstein College of Arts and Sciences at DOCS@RWU. It has been accepted for
inclusion in Feinstein College of Arts & Sciences Faculty Publications by an authorized administrator of DOCS@RWU. For more information, please
contact mwu@rwu.edu.
Recommended Citation
Busch, A. M., Eleanor L. Leavens, Theodore L. Wagener, and Erin M. Tooley. 2016. "Prevalence, Reasons for Use, and Risk Perception
of Electronic Cigarettes among Post-Acute Coronary Syndrome Smokers." Journal of Cardiopulmonary Rehabilitation and Prevention 36
: 352-357.
Prevalence, Reasons for Use, and Risk Perception of Electronic 
Cigarettes among Post-Acute Coronary Syndrome Smokers
Andrew M. Busch, PhD1,2, Eleanor L. Leavens3,4, Theodore L. Wagener4,5, Maria L. 
Buckley1,2, and Erin M. Tooley6
1The Miriam Hospital, Providence, RI
2Warren Alpert Medical School of Brown University, Providence, RI
3Oklahoma State University, Department of Psychology, Stillwater, OK
4University of Oklahoma Health Sciences Center, Oklahoma City, OK
5University of Oklahoma Health Sciences Center, Oklahoma Tobacco Research Center, 
Oklahoma City, OK
6Roger Williams University, Bristol, RI
Abstract
Purpose—The use of electronic cigarettes (e-cigarettes) has risen dramatically in recent years. 
However, there is currently no published data on use of e-cigarettes among cardiac patients. The 
current study reports on the prevalence, reasons for use, and perceived risks of e-cigarettes among 
post-Acute Coronary Syndrome (ACS) patients. The relationship between e-cigarette use and post-
ACS tobacco smoking cessation is also explored.
Methods—Participants were drawn from a randomized trial of smoking cessation treatments 
following hospitalization for ACS. The current study focuses on 49 participants that completed e-
cigarette questions at 24 weeks post-ACS.
Results—51.0% of participants reported ever use of an e-cigarette and 26.5% reported using an 
e-cigarette at some time during the 24 weeks post-ACS. Ever use and post-ACS use were both 
significantly associated with lower rates of abstinence from tobacco cigarettes. Participants 
perceived e-cigarettes as less harmful to cardiac health than tobacco use and Chantix, and similarly 
harmful as nicotine replacement therapy. Participant perceived likelihood of experiencing a heart 
attack in the next year was 34.6% if they were to regularly use e-cigarettes only, significantly 
lower than perceived risk of recurrence if they were to regularly smoke only tobacco cigarettes 
(56.2%) and significantly higher than perceived risk of recurrence if they were to use no nicotine 
(15.2%).
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Conclusions—A significant minority of patients are using e-cigarettes post-ACS. Providers 
should be prepared to discuss potential discrepancies between patient beliefs about the safety of e-
cigarettes and the current state of the science.
Keywords
Electronic cigarettes; acute coronary syndrome; smoking
Electronic cigarettes (e-cigarettes) are battery-powered devices that deliver an inhaled 
aerosol that typically contains nicotine, flavorants, and propylene glycol and/or vegetable 
glycerin. They do not contain tobacco, require combustion, or produce smoke or carbon 
monoxide. While the prevalence of smoking traditional tobacco cigarettes has decreased 
over the past decade, use of e-cigarettes has risen. Between 2010 and 2013 both ever use 
(rose from 3.3% to 8.5%) and current use (rose from 1.0% to 2.6%) of e-cigarettes doubled 
among US adults1. Current and former tobacco cigarette use are the strongest predictors of 
e-cigarette use1, 2. 37% of current tobacco cigarette smokers have ever used an e-cigarette 
and 9.4% are current e-cigarette users1, 3.
Current smokers perceive electronic cigarettes to be significantly less harmful and less likely 
to cause health problems compared to tobacco cigarettes, including the perception that e-
cigarettes are less likely to cause heart disease4. It may be the case that e-cigarettes present 
significantly lower cardiac risk compared to combustible cigarette use, but only preliminary 
data is available on this topic5.
Some data exists on the prevalence of e-cigarette use in medical patients who smoke with 
estimates of current use ranging from 18–27%6–9. To our knowledge, no data exists 
regarding 1) prevalence, reasons for use, or perceived risks of e-cigarettes or 2) the 
relationship between e-cigarette use and cessation of tobacco cigarettes specifically among 
patients with cardiovascular disease. The current study provides data on these issues in a 
sample of post-Acute Coronary Syndrome (ACS) patients participating in a smoking 
cessation trial.
Methods
Participants
Participants in the current study were drawn from participants in a randomized trial of 
smoking cessation treatments following ACS (NCT01964898). For the parent trial, we 
recruited patients that: 1) had an ACS diagnosis documented in their medical record 
(diagnosis of unstable angina, ST elevation myocardial infarction, or non-ST elevation 
myocardial infarction), 2) smoked ≥ 3 tobacco cigarettes per day, 3) were between the ages 
of 18–75, 4) were fluent in English, 5) had regular access to a telephone, 6) lived within a 
one hour drive of their admitting hospital, and 7) were willing to “strongly consider” an 
attempt to quit smoking at discharge. Patients were excluded if they: 1) evidenced limited 
mental competency, 2) presented with psychosis, serious mental illness, or suicidality, 3) 
were not expected to live through the study period or 4) were regularly attending counseling 
for depression or smoking cessation and planned to continue after hospital discharge. 
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Patients who smoked ≥ 3 cigarettes per day who also used other tobacco products (e.g., 
cigars, pipe) or e-cigarettes were allowed to participate.
All participants received smoking cessation counseling during their inpatient stay for ACS 
consistent with the most recent national guidelines10. Subsequently, participants were 
randomly assigned to receive an integrated smoking cessation and mood management 
counseling program or mailed smoking cessation educational materials over 12 weeks after 
hospital discharge. Both conditions were offered an 8-week supply of nicotine patches at 
hospital discharge. Neither treatment specifically encouraged or discouraged e-cigarette use. 
If participants asked about safety of the e-cigarettes or about using them as a way to quit 
smoking, study staff responded that there was not enough evidence on the safety or efficacy 
of e-cigarettes for our team to recommend their use. This approach was consistent with the 
state of e-cigarette research when this protocol was designed in 2011 and is also consistent 
with the current literature11, 12.
Participants were assessed by staff members while in the hospital following ACS and at 12 
and 24 weeks post-discharge. The current study focuses on e-cigarette questions asked at the 
24-week post-discharge assessment, thus we only report on trial participants that completed 
this assessment. All procedures were approved by The Miriam Hospital institutional review 
board.
Measures
At baseline participants self-reported demographics and smoking variables (including the 
Fagerström Test for Cigarette Dependence13 and their confidence in ability to quit smoking 
rated 0–10), and medical history was pulled from clinical charts. At the 24-week assessment, 
patients self-reported if they had attended any cardiac rehabilitation or smoked tobacco 
cigarettes since hospital discharge. Seven-day point prevalence abstinence from tobacco 
cigarettes was established by exhaled carbon monoxide (eCO<10ppm) at the 24-week 
assessment.
All e-cigarette questions were asked at the 24-week assessment. Participants were asked if 
they had “ever used an e-cigarette or vapor device, even one or two times.” We included 
“vapor devices” to ensure that patients included use of so called “second” or “third 
generation” e-cigarette products which are known by a variety of terms (e.g., “hookah pens,” 
“tank systems,” “mods,”) and often look more like large fountain pens than a cigarette. 
Those who endorsed ever use reported date of first use, if they had used since discharge 
from the hospital, and why they tried e-cigarettes for the first time (responses were coded by 
the assessor into one of 15 categories; e.g., “to cut down on other tobacco,” “curiosity,” or 
“to save money”).
Those who reported ever use also reported on the relative perceived harmfulness of e-
cigarettes. Specifically, participants were asked to rate e-cigarettes, the nicotine patch, the 
nicotine gum, the nicotine lozenge, smokeless tobacco, Chantix, and Zyban/Wellbutrin on 
harmfulness to cardiac health on a scale from 0–10, where 0 = “not at all harmful,” and 10 = 
“extremely harmful.” If participants had never heard of a product or did not know anything 
about it, they did not rate harmfulness of that product. In addition, participants were asked to 
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rate from 0–100% “How likely are you to have a heart attack in the next year” if you were to 
1) “regularly smoke only tobacco cigarettes?,” 2) “regularly use e-cigarettes or vapor devices 
only?,” or 3) “quit all nicotine products?”
Results
49 participants completed the questionnaire regarding e-cigarette use at 24 weeks post-ACS. 
The demographics, smoking history, and medical history of these participants are presented 
in Table 1.
51.0% (n=25) of participants reported ever use of an e-cigarette. 28.6% (n=14) reported first 
use before ACS, and 22.4% (n=11) reported first use post-ACS. 26.5% (n=13) reported 
using an e-cigarette at some time during the 24 weeks post-ACS. The most common reasons 
for trying an e-cigarette were “used to quit other tobacco” (60.0%; n=15), “used to cut down 
on other tobacco” (16.0%; (n=4)), and “curiosity” (28.0%; n=7). No other reason was 
endorsed by ≥ 10% of the sample (data not presented).
Of those who reported post-ACS use (n=13), 76.9% (n=10) reported lapsing to tobacco 
cigarettes prior to using an e-cigarette, 15.4% (n=2) used an e-cigarette prior to lapsing to 
tobacco cigarettes, and 7.7% (n=1) never lapsed to tobacco cigarettes following ACS. 12.2% 
(n=6) of all participants reported using an e-cigarette in the 30 days prior to the 24-week 
assessment.
Participants that had ever used an e-cigarette were significantly less likely to be abstinent 
from tobacco cigarettes at 24 weeks (28.0% vs. 70.8%; X2 (1, N = 49) = 8.99, p = .003) and 
to have maintained continuous abstinence post-ACS (16.0% vs. 58.3%; X2 (1, N = 49) = 
9.44, p = .002) than those who had never used an e-cigarette. At baseline, participants that 
had ever used an e-cigarette also reported significantly more lifetime quit attempts 
(U=172.0, p=.01) and significantly lower confidence in their ability to quit (t(47)=2.2, p=.
04) than those who had never used an e-cigarette.
Those that used e-cigarettes during the 24 weeks post-ACS were significantly less likely to 
be abstinent from tobacco cigarettes at 24 weeks (23.1% vs. 58.3%; X2 (1, N=49)=4.75, p 
= .03), to have maintained continuous abstinence (7.7% vs. 47.2%; Fisher exact test p = .02), 
and to accept free nicotine patches provided by the research study (61.5% vs. 91.7%; Fisher 
Exact test p = .02) than those who did not. At baseline, participants that used e-cigarettes 
during the 24 weeks post-ACS also reported significantly more lifetime quit attempts (U = 
143.5; p = .04) and significantly lower confidence in their ability to quit (t(47)=2.1, p=.04) 
than those who did not.
Figure 1 shows participant perceived harm to cardiac health by product among ever users. 
Participants rated e-cigarettes as significantly less harmful to their cardiac health than 
regular tobacco cigarettes (paired t(24) = 10.52, p <.001), smokeless tobacco (paired t(22) = 
7.89, p <.001), and Chantix (paired t(21) = 2.85, p = .01) and similarly harmful as the 
nicotine patch, gum, and lozenge. Participants rated Zyban/Wellbutrin as somewhat more 
harmful than e-cigarettes, but this difference was not significant.
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Participant perceived likelihood of experiencing a heart attack in the next year was 56.2% 
(SD = 28.3%) if they were to regularly smoke only tobacco cigarettes, 34.6% (SD = 27.3%) 
if they were to regularly use e-cigarettes or vapor devices only, and 15.2% (SD = 13.4%) if 
they were to quit all nicotine products. Participants perceived that using e-cigarettes would 
significantly increase the odds of a heart attack relative to no nicotine use (paired t (24)= 
4.59, p <.001), but significantly decrease the odds of a heart attack relative to tobacco 
cigarette use (paired t (24)= 3.87, p = .001).
Discussion
Little is known regarding e-cigarette use among cardiovascular disease patients. This study 
is the first to address this gap in the literature. More than half of the sample reported ever 
using an e-cigarette and just over 12% endorsed current use. Most interestingly, 26.5% of 
our sample reported using an e-cigarette at some time during the 24 weeks post-ACS and 
22.4% reported using an e-cigarette for the first time post-ACS.
Although mixed, the current extant literature favors e-cigarettes helping smokers quit 
tobacco14. Thus, it was interesting that both ever and post-ACS e-cigarette use was 
associated with lower rates of point prevalence and continuous abstinence from tobacco 
cigarettes. We cannot conclude from this data that e-cigarette use caused relapse, particularly 
because the vast majority of post-ACS e-cigarette users relapsed to tobacco cigarettes prior 
to using an e-cigarette. Further, both ever and post-ACS e-cigarette users reported lower 
confidence in their ability to quit smoking and a greater number of previous failed quit 
attempts at baseline which further obscures causality.
Consistent with previous research15, e-cigarettes were rated as less harmful than tobacco 
products and prescription cessation medications, and similarly harmful as nicotine 
replacement therapies. It is difficult to evaluate the accuracy of these perceived differences 
in safety given that data on the safety of e-cigarettes is still emerging. However, existing data 
suggest that patients are likely accurate in their perception that e-cigarettes are less harmful 
that tobacco products, but may be inaccurate in their perception that e-cigarettes are 
similarly (in the case of nicotine replacement therapies) or less harmful (in the case of 
prescription cessation medications) than FDA approved medications.
When asked specifically about one year heart attack risk, participants reported that exclusive 
use of e-cigarettes would reduce risk relative to tobacco use, which is consistent with 
perceptions of general cardiac harm. However, participants also reported that e-cigarettes 
significantly increased the risk of heart attack relative to no nicotine use, suggesting that 
even e-cigarette users believe e-cigarettes have some risk.
These findings have implications for providers, particularly cardiac rehabilitation programs 
which aim to provide comprehensive patient health education post-ACS. National guidelines 
for rehabilitation16 emphasize the importance of smoking as a risk factor, but do not yet 
provide guidance regarding e-cigarettes. The current data indicates that about a quarter of 
smoking patients are using e-cigarettes post-ACS. Thus, rehabilitation providers should 
routinely assess e-cigarette use (particularly among smokers and recent quitters). Providers 
Busch et al. Page 5
J Cardiopulm Rehabil Prev. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
should also be prepared to educate patients regarding e-cigarettes and discuss potential 
discrepancies between patient beliefs about the safety of e-cigarettes and the current state of 
the science. The American Heart Association recently released a policy statement on the use 
of e-cigarettes11 (which is generally consistent with the current policy statements of other 
groups12) that should guide efforts to address e-cigarette use among post-ACS patients. Key 
conclusions of this statement include 1) that there is currently insufficient evidence “for 
clinicians to counsel their patients who are using tobacco products to use e-cigarettes as a 
primary cessation aid” and 2) “If a patient has failed initial treatment, has been intolerant to 
or refuses to use conventional smoking cessation medication, and wishes to use e-cigarettes 
to aid quitting, it is reasonable to support the attempt.” Given that many post-ACS patients 
do not attend rehabilitation, it is important that other post-ACS providers can also provide 
the above education.
This study has some limitations. In particular, the prevalence rates of e-cigarette use among 
ACS patients reported in this study should be interpreted within the context of our modest 
sample size and known regional differences in prevalence rates8. Second, we did not 
distinguish between generations of e-cigarettes in our survey (a limitation because recent 
research has shown substantial differences between generation, including nicotine dose and 
effectiveness for smoking cessation; e.g.,15) or collect data on frequency of e-cigarette use. 
Future work should address these limitations and explore methods of educating both 
providers and ACS patients regarding e-cigarettes.
Conclusion
A significant minority of patients are using e-cigarettes post-ACS. Post-ACS patients believe 
that e-cigarettes are similarly or less harmful than FDA approved medications. Providers 
should be prepared to discuss potential discrepancies between patient beliefs about the 
safety of e-cigarettes and the current state of the science.
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Figure 1. 
Mean Perceived Harmfulness to Cardiac Health (Rated 0–10)
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